| Autor: |
Earnshaw SR; RTI Health Solutions, Research Triangle Park, North Carolina, USA., McDade C; RTI Health Solutions, Research Triangle Park, North Carolina, USA., Bryan A; Pfizer Biopharmaceuticals Group, Pfizer Ltd., Surrey, United Kingdom., Ines M; Hospital & Vaccines Business Unit, Pfizer, Inc., Porto-Salvo, Portugal., Micallef C; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Sung A; Pfizer, Inc., New York, New York, USA., Enoch DA; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. |
| Jazyk: |
angličtina |
| Zdroj: |
Microbiology spectrum [Microbiol Spectr] 2022 Jun 29; Vol. 10 (3), pp. e0042522. Date of Electronic Publication: 2022 May 09. |
| DOI: |
10.1128/spectrum.00425-22 |
| Abstrakt: |
A diagnostic-driven (DD) treatment strategy has proven successful for treating invasive fungal infections (IFIs) caused by Aspergillus. However, uptake of this treatment strategy is not fully embraced. This study compares the economic and clinical impact of DD and empirical-treatment (ET) strategies used within hospitals. Methods: a decision-analytic model was developed to compare costs and clinical outcomes associated with ET or a DD strategy of identifying infections caused by Aspergillus via galactomannan-antigen testing or Aspergillus polymerase chain reaction (PCR) in neutropenic patients with unexplained fever. Patients were treated prophylactically with antifungal treatments as seen in United Kingdom (UK) hospitals. The IFI incidence, response, mortality, resource use, and adverse events were obtained from meta-analyses and other clinical studies. Analyses were performed from the U.K. hospital perspective, and costs were obtained from standard costing sources. Although diagnostic-testing costs increased, total cost and length of stay were reduced by £1,121 and 1.54 days when treating via a DD strategy. Intensive care and general ward days accounted for > 40% of total costs and > 58% of the cost reduction came from reduced antifungal costs. Treating with a DD strategy reduced the number of patients being treated with antifungal agents while survival was increased. Thus, a DD strategy was cost savings (-£136,787 cost per death avoided) compared with an ET strategy. Conclusion: this study suggests that incorporating a DD strategy as the preferred treatment protocol may be a cost-saving and clinically improved treatment strategy for managing neutropenic patients with unexplained fever. IMPORTANCE Patients at risk of invasive fungal infections (IFIs), such as Aspergillus spp., tend to be immunocompromised and usually take several medications which may generate many side effects. Prescribing is further complicated by comorbidities, drug interactions and challenges accessing diagnostics. Therefore, adding another agent may be neither straightforward nor the best option for these types of patients. A diagnostic-driven (DD) treatment strategy has proven successful for treating IFIs. However, uptake of this treatment strategy is not fully embraced in clinical practice perhaps because this strategy is thought to be more costly and/or to result in higher mortality relative to treating empirically. We developed a decision-analytic model to examine the impact of these 2 strategies on costs and health outcomes. This study indicates that incorporating a DD strategy as the preferred treatment protocol may be a cost-saving and clinically improved treatment strategy for managing neutropenic patients with unexplained fever. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
